Kornimate/medical-research-clean huggingface dataset:
detection of covid-19 by volatile organic compounds in exhaled breath

Conditions: Covid19

Summary: our primary aim is to collect breath samples from covid-19 positive patients at the time of diagnosis, during and after recovery using the same patient as his/her own control to identify vocs specific to sars-cov-2 viral infection. a secondary aim is to determine the patient's likely disease trajectory in terms of recovery versus progression to respiratory and or multi-organ failure. breath samples will be collected as soon as the patient is admitted to the vancouver general hospital covid ward with a diagnosis of covid-19 by rt-pcr in nasopharyngeal/throat swab. a second breath sample will be obtained one week later, or before hospital discharge or if they become sicker prior to transfer to the intensive care. a third sample will be taken to 8-12 weeks after recovery from the illness with a negative covid-19 rt-pcr test. vocs in exhaled breath will be measured by gas chromatography-mass spectrometry (gc-tof-ms or gcxgc-tofms). voc profiles from the symptomatic phase and recovery phase will be compared to determine if there are unique vocs associated with covid-19 infection. comparison of voc profiles between those who recover and those who progressed will provide information on potential prognostic features. the results of this pilot study will form the basis to determine if a larger study is warranted.

patients will be recruited from the covid wards at vgh, all patients admitted will be given a letter of invite on admission if eligible and if interested and eligible will be enrolled. sample for the study will be collected at the vgh covid patient wards. consenting patients and breath collection will be performed in the patients' hospital room with proper personnel protective equipment. a verbal consent will be collected as to not contaminate consent forms. a paper copy will be given or emailed to the participants to have for their own records. .we aim to recruit up to 20 patients. the final number will be dependent on the number of new cases in vancouver available for the study after reb approval. additional participants will be recruited from community testing sites. participants will be approached to be invited to participate while waiting in their vehicles at the drive-by testing sites. breath samples will be analyzed on a sepsolve gc-tof ms system at the bc cancer research institute.

Eligibility criteria:
inclusion criteria: * are between the ages of 18 and 85 years * are test positive for covid-19 (sars-cov-2) * are capable of providing informed consent to participate in the study exclusion criteria: * too sick to provide a breath sample * unwilling to sign a consent * unwilling to be followed up after you have recovered from the illness.
mechanical traction force and knee joint space

Conditions: Knee Arthritis

Summary: the purposes of this crossover study are to purpose 1. to determine the most effective traction force for knee joint that can be used in the treatment of patients with koa. 2. to determine the influence of knee joint traction on rom ok knee joint flexion and extension 3. to determine the influence of knee joint traction on the flexibility of hamstring muscles

this study is a pilot study design aiming to determine the most effective mechanical traction force used for knee joint treatment. this effectiveness was assessed in favor of the separation of the joint surfaces in cm in addition to the hamstring flexibility measured in cm and active knee flexion range of motion. according to previous literature, there is no consensus regarding the most appropriate traction force that can produce statistical and clinically meaningful differences so we started this pilot study. the results of this study will be used to conduct a larger-scale study using the most appropriate traction force on patients having knee osteoarthritis.

Eligibility criteria:
inclusion criteria: 1. healthy subject 2. males or females 3. no previous surgery in lower limbs exclusion criteria: 1. diseased knee joint 2. knee osteoarthritis 3. any musculoskeletal problem in the lower extremities 4. varicose veins 5. pregnancy
anesthesia neurodevelopmental impact in congenital scoliosis children

Conditions: General Anesthetics Toxicity

Summary: in the past, a large number of animal studies have suggested that anesthesia exposure has potential neurotoxic effects, resulting in persistent cognitive and behavioral deficits. at present, there is still a lack of sufficient clinical research evidence to prove whether anesthesia exposure has long-term effects on neurodevelopment. the existing clinical research data suggests that a single short-time anesthesia exposure in young children does not affect long-term neurodevelopmental outcomes. early onset scoliosis, including congenital scoliosis, is a type of scoliosis deformity that occurs before the age of 10. posterior scoliosis correction surgery is one of the common treatment. there is currently no research indicating the impact of early single or multiple long-duration anesthesia exposure on the neurological development of children with congenital scoliosis. the aim of this study is to determine the long-term effect of general anesthesia exposure on neurocognitive function and behavior in children with congenital scoliosis, in order to provide reference for related clinical work.


Eligibility criteria:
inclusion criteria: * diagnosed with congenital scoliosis * 6-16 years old at the time of assessment exclusion criteria: * cognitive impairment caused by congenital, traumatic or other reasons; * existence of mental or psychological disorders; * there are factors that may affect neurological development, including any known central nervous system disease, neurological injury, or history of neonatal asphyxia; * unable to cooperate with cognitive function tests; * the child is unable to communicate in chinese.
a preliminary study of a new tranexamic acid dosing schedule for cardiac surgery

Conditions: Cardiac Surgery

Summary: tranexamic acid is administered intravenously to prevent bleeding associated with cardiac surgery and cardiopulmonary bypass. we have developed an assay for tranexamic acid. we have developed an alternative dosing schedule for tranexamic acid. the objective of this preliminary study is to determine if this new dosing schedule can achieve the desired plasma concentration of tranexamic acid and reduce intra and inter patient variability in tranexamic acid plasma concentrations relative to the current dosing schedule.

tranexamic acid is administered intravenously to prevent bleeding associated with cardiac surgery and cardiopulmonary bypass. the current dosing regimen for tranexamic acid was empirically derived based upon pharmacokinetics in normal patients receiving the drug. we have developed an assay for tranexamic acid and found that the plasma concentration of tranexamic acid varies greatly between patients and also over time within each patient, especially in patients with renal insufficiency. we have developed an alternative dosing schedule for tranexamic acid that incorporates the effects of renal function on tranexamic acid concentrations. the objective of this preliminary study is to determine if this new dosing schedule can achieve the desired plasma concentration of tranexamic acid and reduce intra and inter patient variability in tranexamic acid plasma concentrations relative to the current dosing schedule. the results of this study will be used in a larger subsequent study of what level of plasma tranexamic acid concentration is needed to prevent bleeding and transfusion of blood products in patients undergoing cardiac surgery.

Eligibility criteria:
inclusion criteria: * age 18 years old or greater having cardiac surgery. exclusion criteria: * age less than 18 years old. * since tranexamic acid is not approved for pregnant patients, those extremely rare patients that are pregnant and having cardiac surgery will be excluded from the study

Keywords: antifibrinolytic, bleeding, heart
on-line intervention for promoting healthy habits and weight loss in hypertensive patients

Conditions: Obesity

Summary: efficacy of an internet-based self-guided intervention for promoting healthy habits and weight loss in hypertensive people with overweight and obesity: a randomized controlled trial

the prevalence of overweight and obesity is on the rise worldwide with severe physical and psychosocial consequences. hypertension is one of the comorbidities associated with obesity. changes in lifestyles through eating behavior and physical activity level are the critical components in the prevention and treatment for hypertension and obesity. data from several studies indicate that the usual procedures to promote these healthy habits in health services are inadequate. icts has been demonstrated as an effective tool for implementation of psychological interventions focused on this type of population. this study aims to describe a totally self-applied online program (¨vivir mejor¨) to promote healthy lifestyles (eating behavior and physical activity) for obese participants with hypertension. participants (bmi=25-35) will be recruited from users of a hypertension unit of a public hospital and will be randomized into two groups: experimental group "vivir mejor" and control group (treatment as usual). "vivir mejor" program is composed by 9 modules aimed for promoting healthy eating habits and increase physical activity. modules will be sent via internet periodically. after 6 months, a follow-up testing phase and a tracking module will be set. the outcomes variables will include anthropometric data, changes in eating behavior and physical performance and cardiovascular variables.

Eligibility criteria:
inclusion criteria: * overweight or obese grade i (bmi\> 25 and \<35) * age between 18-65 years * being in clinical medical treatment for prevention of metabolic syndrome or cardiac complications * having internet access. exclusion criteria: * no internet access; taking more than 3 antihypertensive drugs * have diabetes diagnosis; meet the dsm-iv-tr of eating disorder * submit a serious psychological disorder diagnosed (psychosis, bipolar disorder, major depressive disorder, substance abuse) * have a disability which prevents or hinders the exercise and physical activity * be receiving any treatment for weight loss in another center.

Keywords: obesity internet intervention cardiovascular disease hypertension lifestyle intervention weight loss treatment
study of a diagnostic device for identifying between amniotic fluid to urine

Conditions: Amniotic Fluid Leakage

Summary: the purpose of this study is to compare the reliability and validity of a new device with standard methods for diagnosing between amniotic fluid leakage due to premature rupture of the membranes (prom) and urine.

pregnant women sensing wetness and arriving to the delivery room with suspect prom will use a self-testing device to test whether the wetness is caused by amniotic fluid leakage or urinary incontinence. clinical evaluation will be performed to all pregnant women using standard clinical tests. the results of the standard clinical tests will be compared to the women's reading of the self-testing device results. sensitivity and specificity of the device evaluation will be calculated.

Eligibility criteria:
inclusion criteria: 1. pregnant women age 18 years and older attending delivery room. 2. stage of gestation: pregnancy between 16 and 42 weeks of gestation. 3. able and willing to read and sign an informed consent document. exclusion criteria: subjects will be excluded from the study if any of the following will be present: 1. prior use of any amniotic fluid detection test. 2. use of vaginal douching apparatus (such as a vaginal bulb syringe) or vaginal products such as creams or gels within the past 24 hours. 3. vaginal bleeding or spotting or excess abnormal vaginal discharge within the past 24 hours. 4. sexual intercourse within the past 24 hours. 5. confirmed diagnosis of any vaginal infection within the past 7 days. 6. use of vaginal products or antibiotic treatments that reduce bacterial population or use of medications such as tamoxifen that reduce estrogen levels or antihistamines that dry mucous membranes within the past 7 days.. 7. patients unable or unwilling to participate. 8. patients in active labor (or with regular contractions).

Keywords: amniotic fluid leakage urinary incontinence
continuous sciatic nerve block vs epidural analgesia in lower limb amputation for postoperative pain

Conditions: Phantom Limb Pain; Pain, Chronic

Summary: controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants

controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants outcomes: primary: numeric rating scale (nrs) ranging from 0 (no pain) to 10 (worst imaginable pain) was used for pain assessments daily for 15 days and subsequently monthly until completing 3 months. co-primary: assessment of symptomatology related to phantom limb pain daily for 15 days pop and subsequently monthly until completing 3 months.

Eligibility criteria:
inclusion criteria: 1. age over 18 years 2. being scheduled for above or below knee amputation or for bone remodeling of lower limb amputees 3. acceptance of continuous regional analgesic technique as part of their multimodal analgesia exclusion criteria: 1. traumatic cause of amputation 2. allergy to local anesthetics 3. contraindication for epidural technique or continuous blocks 4. stage 5 kidney disease 5. concomitant use of aspirin and clopidogrel 6. pregnancy status
adalimumab in adult japanese subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to assess the long-term safety, tolerability, and efficacy of repeated administration of adalimumab in adult japanese subjects with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * participation in the prior adalimumab study * body weight less than 100 kg. * subject's who wished to continue the study drug administration * females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion. exclusion criteria: * a subject who experienced any of the following during the prior adalimumab sc dosing study: * advanced or poorly controlled diabetes * any poorly controlled medical condition * intra-articular, intramuscular or iv administration of corticosteroids * joint surgery. * a subject who has been prescribed excluded medications during previous adalimumab study. * history of clinically significant drug or alcohol abuse, intravenous (iv) drug abuse, active infection with listeria or tuberculosis (tb), lymphoma, leukemia, or any malignancy with the exception of successfully treated non- metastatic basal cell carcinoma of the skin. * a subject who experienced chronic or active infection or any major episode of infection requiring hospitalization or treatment with intravenous (iv) antibiotics within 30 days of entry into study or chronic use of oral antibiotics within 14 days of entry into study. * preexisting or recent onset of central nervous system (cns) demyelinating disorders.

Keywords: rheumatoid arthritis
exercise and vascular function in postmenopausal females with hypertension

Conditions: Hypertension

Summary: the treatment of high blood pressure, or hypertension, is multifaceted and can include pharmacological therapies (i.e., medications) and lifestyle modifications such as physical activity. chronotherapy, which describes timing of a treatment with the body's daily rhythms, has recently been used with hypertension medications and has been shown to be effective at lowering blood pressure and reducing the risk of cardiovascular disease events. specifically, taking medications in the evening was shown to be more effective than morning medication routines. little information is available about the effectiveness of chronotherapy combined with exercise (i.e., planned physical activity) interventions in older adults with hypertension. the purpose of this study is to examine how exercise performed in the morning and early evening affects blood pressure and other measures of blood vessel health in postmenopausal females with hypertension.

blood pressure has an internal rhythm associated with the 24-hr clock. nocturnal blood pressure (bp) is a key contributor to cardiovascular health and may be improved by exercise. moreover, the time of day of the exercise may be a key factor. this study aims to evaluate the effect of evening exercise on bp and other measures of vascular function in older females with hypertension.

Eligibility criteria:
inclusion criteria: * systolic bp equal to or greater than 130 mmhg without bp medication or greater than 120 mmhg with medication and diastolic blood pressure equal to and greater than 80 mmhg * 55-80 years old * post-menopausal female * able to walk without assistance exclusion criteria: * habitually physically active defined as 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic physical activity per week * overt pulmonary disease/condition as follows: chronic bronchitis, chronic obstructive pulmonary disease, emphysema, or pulmonary hypertension * cardiometabolic disease/condition as follows: diabetes, heart failure, peripheral arterial disease, stroke, coronary artery disease, renal disease, secondary hypertension, chronic venous insufficiency or deep vein thrombosis within last 6 months * cancer within last 5 years * body mass index \>39 kg/m2 * current smoking or vape * evening shift work
impact of butyricicoccus pullicaecorum in healthy subjects

Conditions: Healthy

Summary: during this project the safety, tolerability and effect on gut microbiota of oral administration of butyricicoccus pullicaecorum was investigated in healthy human volunteers by a placebo-controlled cross-over randomized study.

intervention periods were 4 weeks, with daily intake of 1 capsule. wash-out periods were 3 weeks.

Eligibility criteria:
inclusion criteria: * bmi between 18 and 28 kg/m² * good general health * regular eating pattern (3 meals/day on at least 5 days/week) exclusion criteria: * chronic gastrointestinal disease (crohn's disease, ulcerative colitis, irritable bowel syndrome, chronic constipation or chronic diarrhea) * surgery of the gastrointestinal tract (except for an appendectomy) * use of antibiotics during the month preceding the study * use of medication or dietary supplements influencing gut transit or intestinal microbiota during the month preceding the study. examples of such medication/dietary supplements are antispasmodics (e.g. buscopan), antidiarrheal medication (e.g. imodium), probiotic medication (e.g. lacteol, enterol) * intake of pre- or probiotics during the study or during the month preceding the study * being on a weight-loss diet during the study or during the month preceding the study * extreme dietary habits (e.g. vegan, atkins diet, montignac diet) * females who are pregnant, lactating or planning to become pregnant during the study period
study of bendamustine/rituxan induction chemotherapy with revlimid maintenance for relapsed/refractory cll and sll

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of this research is to evaluate a new combination of chemotherapy drugs for cll/sll using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). the purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.


Eligibility criteria:
inclusion criteria: * histologically confirmed,cll/sll, documented relapsed or refractory disease after at least one prior chemotherapy regimen. * in cases of sll, patients must have at least one bidimensionally measurable lesion at least ≥1.5 cm measured in one dimension. * ecog performance status of 0-2 at study entry * laboratory test results within these ranges: anc \<=1500/μl, platelet count \<= 100,000/μl. patients with anc \<1500/μl or plt \<100,000/μl with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligible. * creatinine clearance of \>60 ml/min as determined by the cockcroft-gault calculation. * total bilirubin \<= 2x upper limit laboratory normal (uln). patients with non-clinically significant elevations of bilirubin due to gilbert's disease are not required to meet these criteria. * serum transaminases ast (sgot) and alt (sgpt) \<=5x uln, serum alkaline phosphatase ≤5 x uln. * disease free of prior malignancies for ≥ 2 years with the exception of basal or squamous cell skin carcinoma, carcinoma "in situ" of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery). * patients may have received prior therapy with bendamustine or lenalidomide, but must not have disease that is refractory to bendamustine or lenalidomide. * prior therapy with rituximab is permitted, even in the setting of rituximab refractory disease. exclusion criteria: * has received \>5 lines of prior therapy for their disease. re-treatment with an identical regimen does not count as a new regimen. * any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form or comply with the protocol treatment. * pregnant or breast feeding females. lactating females must agree not to breast feed while taking lenalidomide. * prior history or current evidence of central nervous system or leptomeningeal involvement. * use of any other experimental drug or therapy within 28 days of baseline. * known hypersensitivity to thalidomide. * the development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * known to be positive for hiv or infectious hepatitis, type b or c.

Keywords: cll sll